News
NONOF
41.60
+0.85%
0.35
Novo Nordisk marks more than 3M Wegovy pill prescriptions
Seeking Alpha · 21h ago
Novo Nordisk: The Biggest Healthcare Bargain
Seeking Alpha · 1d ago
Weekly Report: what happened at NONOF last week (0601-0605)?
Weekly Report · 2d ago
Employers scale back coverage of weight-loss drugs as costs surge
Seeking Alpha · 2d ago
Amgen: Time For An Upgrade? Yes, I Think So
Seeking Alpha · 4d ago
Madrigal Pharmaceuticals Could Become The Next Vertex
Seeking Alpha · 06/03 01:40
Omeros: Launch Traction Encouraging, But Risk/Reward Looks Balanced (Initiating Hold)
Seeking Alpha · 06/02 07:42
Weekly Report: what happened at NONOF last week (0525-0529)?
Weekly Report · 06/01 09:54
Novo is slowly catching up with Lilly: Is Wegovy pill fueling the rally
Seeking Alpha · 05/30 16:49
Agios: 'Sell' On Tebapivat Setback LR-MDS And Competitive PK Activator Drug Class
Seeking Alpha · 05/29 20:11
France to become first EU nation to cover weight-loss meds
Seeking Alpha · 05/28 14:43
Wall Street Underestimates Novo Nordisk's GLP-1 Comeback
Seeking Alpha · 05/28 12:59
CVS Health reintroduces coverage for Lilly’s Zepbound
Seeking Alpha · 05/28 11:35
Weekly Report: what happened at NONOF last week (0518-0522)?
Weekly Report · 05/25 09:56
Novo gets EU backing for higher-dose Wegovy in single-dose pen
Seeking Alpha · 05/22 18:10
Novo Nordisk wins EU endorsement for Wegovy pill
Seeking Alpha · 05/22 12:41
These Are The Upcoming Catalysts For Crispr Therapeutics Stock
Seeking Alpha · 05/21 21:40
How does Lilly’s next-gen obesity drug compare to Novo’s
Seeking Alpha · 05/21 16:27
Hims & Hers launches generics for Novo’s semaglutide in Canada
Seeking Alpha · 05/21 13:29
GoodRx: TrumpRx Exposes Legacy Moat Breach And Zero-Sum Strategy (Downgrade)
Seeking Alpha · 05/20 15:46
More
Webull provides a variety of real-time NONOF stock news. You can receive the latest news about Novo-Nordisk A S through multiple platforms. This information may help you make smarter investment decisions.
About NONOF
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.